Key result
First-line systemic treatment for metastatic synovial sarcoma was associated with a median overall survival of 24.5 months, while time to treatment discontinuation decreased in subsequent lines.
Why the study?
To examine and understand patient characteristics, treatment patterns, and outcomes for patients with metastatic synovial sarcoma treated in a US community setting.
Observational (n=71)
Yes
Real-world data in metastatic synovial sarcoma shows decreasing time to treatment discontinuation with subsequent lines of therapy and a median overall survival of 24.5 months from first-line treatment.
Aim: To examine and understand patient characteristics, treatment patterns and outcomes for patients with metastatic synovial sarcoma (mSS) treated in a US community setting. Materials & methods: Retrospective observational study in adults with mSS in The US Oncology Network (diagnosed January 2012–December 2018). Results: Of 202 patients diagnosed with SS, 71 had mSS. Of 39 patients with mSS who received first-line (1L) systemic treatment, 25 and 16 continued to second-line and 3L+ treatment, respectively. With each subsequent treatment line, time to treatment discontinuation (1L–3L: 3.9–2.7 months) and time to next treatment (1L–3L: 9.3–4.6 months) decreased. At 1L, median overall survival was 24.5 months. Conclusion: This study highlights the ongoing need for effective therapies for mSS.
No takes yet. Share an insight, caveat, or question.
Pokras et al. (2022) conducted an observational in Metastatic synovial sarcoma (n=71). Systemic treatment was evaluated on Overall survival. First-line systemic treatment for metastatic synovial sarcoma was associated with a median overall survival of 24.5 months, while time to treatment discontinuation decreased in subsequent lines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: